Print Page   |   Sign In   |   Register
Companies: RXi Pharmaceuticals (RXII)

Company Profile


RXi Pharmaceuticals Corporation (OTCQX:RXII) is a biotechnology company focused on discovering, developing, and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence" or down-regulate, the expression of a specific gene that may be expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human trial in 2012. RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.  

Company Officers/Contacts

Dr. Geert Cauwenbergh Ph.D., Med.Sc. - Chief Exec. Officer, Pres, Acting Chief Financial Officer, Director and Member of Nominating & Governance Committee
Dr. Pamela A. Pavco Ph.D. - Chief Devel. Officer
Ms. Caitlin Kontulis - Principal Accounting Officer, Director of Fin., Sec. and Controller
Dr. Karen Bulock Ph.D. - VP of Research
Dr. Lyn Libertine M.D. - VP of Medical Affairs & Safety Assessment

Contact Information

  • 257 Simarano Drive
  • Suite 101
  • Marlborough, MA 01752

Financial Reporting/Disclosure

Reporting Status U.S. Reporting: SEC Reporting
Latest Report Mar 31, 2016 10-Q
Regulatory Agency Financial Industry Regulatory Authority
CIK 0001533040
Fiscal Year End 12/31
OTC Marketplace Not Available

Profile Data

SIC - Industry Classification Not Available
Incorporated In: DE, USA
Year of Inc. 2011
Employees 10 a/o Apr 30, 2013
Service Providers
Accounting/Auditing Firm
945 E Park Drive
Suite 103
Harrisburg, PA, 17111
United States

Legal Counsel
Ropes & Gray
3 Embarcadero Center
San Francisco, CA, 94111
United States

Investor Relations Firm
Not Available


Community Search
Sign In